HER2 Support Group Forums - View Single Post - New data shows abemaciclib continues to benefit high-risk, HR+, HER2-, early-stage br

News · 12-09-2020, 05:54 PM

Extended follow-up data from the phase III monarchE trial showed that adding the cyclin-dependent kinase (CDK) inhibitor abemaciclib (Verzenio) to standard adjuvant endocrine therapy continued to improve invasive disease-free survival (IDFS) among patients with high-risk, node-positive, early-stage, HR-positive, HER2-negative breast cancer, according to data presented at the 2020 San Antonio Breast Cancer Symposium, held Dec. 8-11.

More...

12-09-2020, 05:54 PM	#1
News Senior Member Join Date: Oct 2007 Posts: 18,983	New data shows abemaciclib continues to benefit high-risk, HR+, HER2-, early-stage br Extended follow-up data from the phase III monarchE trial showed that adding the cyclin-dependent kinase (CDK) inhibitor abemaciclib (Verzenio) to standard adjuvant endocrine therapy continued to improve invasive disease-free survival (IDFS) among patients with high-risk, node-positive, early-stage, HR-positive, HER2-negative breast cancer, according to data presented at the 2020 San Antonio Breast Cancer Symposium, held Dec. 8-11. More...